Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Body Mass Index (BMI)
Timeframe: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Prostate-Specific Antigen (PSA)
Timeframe: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Alkaline Phosphatase (P-AFOS)
Timeframe: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Length of Follow-up
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With de Novo Metastasis
Timeframe: Within 2 months from index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Who Received Treatment for mCRPC and mCSPC
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Diagnosed With mCSPC Who Progressed to mCRPC
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With Orchiectomy
Timeframe: Closest record any time from index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Undergone Palliative Radiology
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With Symptomatic Skeletal-Related Event (SSRE)
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With Osteoporosis
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Who Were on Bone Medication
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Who Were on Opioids
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Classified Per Charlson Comorbidity Index (CCI) Scores
Timeframe: Up to 5 years before the index date (index date included); retrospective available data evaluated in this study for approximately 14 months
Number of Participants Classified Per Gleason Score
Timeframe: Closest record any time from index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approx.14 months
Number of Participants Based on Tumor Node Metastasis (TNM) Classification: T
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Based on Tumor Node Metastasis (TNM) Classification: N
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Based on Tumor Node Metastasis (TNM) Classification: M
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Based on Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants According to Treatment Per Treatment Line for mPC: mCSPC Participants
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants According to Treatment Per Treatment Line for mPC: mCRPC Participants
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Overall Survival (OS)
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Time to Next Treatment (TTNT)
Timeframe: From initiation of current treatment line until initiation of next treatment line, death censoring event, whichever occurred first, maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Time to Disease Progression
Timeframe: From mCSPC index until mCRPC index, death or censoring event, whichever occurred first, maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Per Factors Associated With Disease Progression to Castration Resistant
Timeframe: From mCSPC index until mCRPC index, death or censoring event, whichever occurred first, maximum up to 24 months; retrospective available data evaluated in this study for approximately 14 months
Annual Incidence of mPC, mCSPC and mCRPC
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Events Per Participant Year for Outpatient Clinic Contacts, Hospitalization Contacts
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx. 9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Days Per Participant Year for Hospital Inpatient Days
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx. 9 years; retrospective available data evaluated in this study for approximately 14 months